Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
1962
mi
from 91732
Royal Oak, MI
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
1962
mi
from 91732
Royal Oak, MI
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
1511
mi
from 91732
Minneapolis, MN
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
1511
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
1341
mi
from 91732
Kansas City, MO
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
1341
mi
from 91732
Kansas City, MO
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
2435
mi
from 91732
New York, NY
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
2093
mi
from 91732
Statesville, NC
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
2093
mi
from 91732
Statesville, NC
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
1880
mi
from 91732
Cincinnati, OH
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
1357
mi
from 91732
Houston, TX
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
964
mi
from 91732
Seattle, WA
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
964
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
2452
mi
from 91732
Montreal,
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
2452
mi
from 91732
Montreal,
Click here to add this to my saved trials
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
2103
mi
from 91732
Gainesville, FL
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
2103
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
1880
mi
from 91732
Cincinnati, OH
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
1188
mi
from 91732
San Antonio, TX
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated:  8/1/2016
5808
mi
from 91732
Heidelberg,
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated: 8/1/2016
5808
mi
from 91732
Heidelberg,
Click here to add this to my saved trials
Patient-Reported Preferences Affecting Revascularization Decisions
Patient-Reported Preferences Affecting Revascularization Decisions
Status: Enrolling
Updated:  8/2/2016
Duke University Hospital
2198
mi
from 91732
Durham, NC
Patient-Reported Preferences Affecting Revascularization Decisions
Patient-Reported Preferences Affecting Revascularization Decisions
Status: Enrolling
Updated: 8/2/2016
Duke University Hospital
2198
mi
from 91732
Durham, NC
Click here to add this to my saved trials
School-Based Intervention to Increase Physical Activity Among Adolescent Females
Interventions to Increase Adolescent Physical Activity
Status: Enrolling
Updated:  8/2/2016
The University of Maryland
2290
mi
from 91732
College Park, MD
School-Based Intervention to Increase Physical Activity Among Adolescent Females
Interventions to Increase Adolescent Physical Activity
Status: Enrolling
Updated: 8/2/2016
The University of Maryland
2290
mi
from 91732
College Park, MD
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1777
mi
from 91732
Birmingham, AL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1744
mi
from 91732
Northport, AL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1744
mi
from 91732
Northport, AL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
343
mi
from 91732
Phoenix, AZ
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
427
mi
from 91732
Tucson, AZ
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
324
mi
from 91732
Spring Valley, CA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
324
mi
from 91732
Spring Valley, CA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
22
mi
from 91732
Torrance, CA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
22
mi
from 91732
Torrance, CA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
345
mi
from 91732
Walnut Creek, CA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
345
mi
from 91732
Walnut Creek, CA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
2315
mi
from 91732
Fort Lauderdale, FL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
2315
mi
from 91732
Fort Lauderdale, FL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
2131
mi
from 91732
Jacksonville, FL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
2131
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
2306
mi
from 91732
Pembroke Pines, FL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
2306
mi
from 91732
Pembroke Pines, FL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1730
mi
from 91732
Chicago, IL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1793
mi
from 91732
Indianapolis, IN
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1656
mi
from 91732
Lacombe, LA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1656
mi
from 91732
Lacombe, LA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1666
mi
from 91732
Slidell, LA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1666
mi
from 91732
Slidell, LA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
2615
mi
from 91732
Auburn, ME
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
2615
mi
from 91732
Auburn, ME
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
2435
mi
from 91732
New York, NY
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
2093
mi
from 91732
Statesville, NC
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
2093
mi
from 91732
Statesville, NC
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1880
mi
from 91732
Cincinnati, OH
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1161
mi
from 91732
Oklahoma City, OK
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1161
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
2281
mi
from 91732
Camp Hill, PA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
2281
mi
from 91732
Camp Hill, PA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
2373
mi
from 91732
Philadelphia, PA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1285
mi
from 91732
Bryan, TX
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1285
mi
from 91732
Bryan, TX
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1357
mi
from 91732
Houston, TX
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
1184
mi
from 91732
San Antonio, TX
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
1184
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
573
mi
from 91732
Salt Lake City, UT
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
573
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
2341
mi
from 91732
Norfolk, VA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
2341
mi
from 91732
Norfolk, VA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
2269
mi
from 91732
Richmond, VA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
6113
mi
from 91732
Buenos Aires,
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
6113
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Hudson Heart Group, PC
2432
mi
from 91732
Guttenberg, NJ
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Hudson Heart Group, PC
2432
mi
from 91732
Guttenberg, NJ
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Elmhurst Hospital
2439
mi
from 91732
Elmhurst, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Elmhurst Hospital
2439
mi
from 91732
Elmhurst, NY
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Winthorp University Hospital
2451
mi
from 91732
Mineola, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Winthorp University Hospital
2451
mi
from 91732
Mineola, NY
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Icahn School of Medicine at Mount Sinai
mi
from 91732
New York, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Icahn School of Medicine at Mount Sinai
mi
from 91732
New York, NY
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Stony Brook University Hospital
2503
mi
from 91732
Stony Brook, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Stony Brook University Hospital
2503
mi
from 91732
Stony Brook, NY
Click here to add this to my saved trials
Coronary Flow Reserve Following Orbital Atherectomy
Coronary Flow Reserve Following Orbital Atherectomy and Percutaneous Revascularization in Severely Calcified Coronary Lesions
Status: Enrolling
Updated:  8/10/2016
Chandler Regional Medical Center and Mercy Gilbert Medical Center
356
mi
from 91732
Chandler, AZ
Coronary Flow Reserve Following Orbital Atherectomy
Coronary Flow Reserve Following Orbital Atherectomy and Percutaneous Revascularization in Severely Calcified Coronary Lesions
Status: Enrolling
Updated: 8/10/2016
Chandler Regional Medical Center and Mercy Gilbert Medical Center
356
mi
from 91732
Chandler, AZ
Click here to add this to my saved trials